Nikita Pozdeyev
Concepts (335)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 15 | 2026 | 327 | 4.140 |
Why?
| | Thyroid Nodule | 2 | 2025 | 55 | 1.660 |
Why?
| | Thyroid Carcinoma, Anaplastic | 4 | 2020 | 33 | 1.460 |
Why?
| | Retina | 13 | 2012 | 314 | 1.080 |
Why?
| | Multiple Endocrine Neoplasia Type 2a | 1 | 2025 | 14 | 0.950 |
Why?
| | Hamartoma Syndrome, Multiple | 1 | 2025 | 17 | 0.950 |
Why?
| | Adenomatous Polyposis Coli | 1 | 2025 | 38 | 0.930 |
Why?
| | Adrenal Cortex Neoplasms | 2 | 2021 | 63 | 0.790 |
Why?
| | Adrenocortical Carcinoma | 2 | 2021 | 66 | 0.790 |
Why?
| | Carcinoma | 1 | 2025 | 230 | 0.790 |
Why?
| | Thyroxine | 1 | 2023 | 64 | 0.780 |
Why?
| | Melatonin | 9 | 2009 | 163 | 0.760 |
Why?
| | Hypothyroidism | 1 | 2023 | 73 | 0.760 |
Why?
| | Adenoma | 1 | 2025 | 221 | 0.760 |
Why?
| | Dopamine | 11 | 2018 | 309 | 0.740 |
Why?
| | Circadian Rhythm | 10 | 2011 | 515 | 0.720 |
Why?
| | Proto-Oncogene Proteins B-raf | 6 | 2023 | 223 | 0.710 |
Why?
| | Artificial Intelligence | 1 | 2026 | 337 | 0.710 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2020 | 34 | 0.630 |
Why?
| | Splenectomy | 1 | 2020 | 62 | 0.630 |
Why?
| | Bacterial Vaccines | 1 | 2020 | 63 | 0.620 |
Why?
| | Biomarkers, Tumor | 5 | 2024 | 1258 | 0.600 |
Why?
| | Antigens, Neoplasm | 1 | 2020 | 322 | 0.540 |
Why?
| | Ultrasonography | 3 | 2026 | 761 | 0.500 |
Why?
| | Pharmacogenomic Testing | 1 | 2016 | 61 | 0.480 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2021 | 833 | 0.470 |
Why?
| | Guideline Adherence | 1 | 2020 | 566 | 0.460 |
Why?
| | Databases, Genetic | 1 | 2016 | 243 | 0.450 |
Why?
| | Antineoplastic Agents | 2 | 2016 | 2169 | 0.430 |
Why?
| | NF-kappa B | 2 | 2015 | 692 | 0.430 |
Why?
| | Photoreceptor Cells, Vertebrate | 3 | 2012 | 26 | 0.410 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2024 | 1078 | 0.410 |
Why?
| | Sepsis | 1 | 2020 | 621 | 0.400 |
Why?
| | Data Collection | 1 | 2016 | 662 | 0.400 |
Why?
| | Mutation | 9 | 2021 | 4015 | 0.400 |
Why?
| | Genetic Variation | 1 | 2018 | 1000 | 0.390 |
Why?
| | Thyroidectomy | 3 | 2024 | 97 | 0.370 |
Why?
| | Photoreceptor Cells | 3 | 2008 | 17 | 0.370 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1570 | 0.360 |
Why?
| | Genomics | 4 | 2024 | 815 | 0.350 |
Why?
| | Eye Proteins | 3 | 2008 | 93 | 0.300 |
Why?
| | Adenocarcinoma, Follicular | 2 | 2019 | 34 | 0.300 |
Why?
| | Signal Transduction | 4 | 2018 | 5169 | 0.300 |
Why?
| | GTP-Binding Protein Regulators | 1 | 2008 | 2 | 0.290 |
Why?
| | Humans | 30 | 2026 | 141754 | 0.280 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2021 | 204 | 0.280 |
Why?
| | Arylalkylamine N-Acetyltransferase | 2 | 2006 | 2 | 0.270 |
Why?
| | Cell Line, Tumor | 8 | 2021 | 3495 | 0.270 |
Why?
| | 14-3-3 Proteins | 1 | 2006 | 16 | 0.250 |
Why?
| | Phosphoproteins | 1 | 2008 | 338 | 0.240 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2025 | 35 | 0.240 |
Why?
| | 3,4-Dihydroxyphenylacetic Acid | 7 | 2011 | 19 | 0.230 |
Why?
| | United Kingdom | 1 | 2025 | 322 | 0.220 |
Why?
| | Thyroglobulin | 1 | 2024 | 27 | 0.220 |
Why?
| | PTEN Phosphohydrolase | 1 | 2025 | 163 | 0.220 |
Why?
| | MAP Kinase Signaling System | 2 | 2023 | 326 | 0.210 |
Why?
| | Kynuramine | 1 | 2003 | 1 | 0.210 |
Why?
| | Lighting | 2 | 2000 | 30 | 0.200 |
Why?
| | Biological Clocks | 4 | 2008 | 46 | 0.200 |
Why?
| | Computers | 1 | 2023 | 68 | 0.200 |
Why?
| | Dopamine Agents | 2 | 2018 | 21 | 0.200 |
Why?
| | Levodopa | 2 | 2018 | 39 | 0.190 |
Why?
| | Thyrotropin | 1 | 2023 | 117 | 0.190 |
Why?
| | Neoplasm Staging | 2 | 2018 | 1401 | 0.190 |
Why?
| | Data Warehousing | 1 | 2022 | 5 | 0.190 |
Why?
| | Cloud Computing | 1 | 2022 | 7 | 0.190 |
Why?
| | Models, Genetic | 1 | 2025 | 592 | 0.180 |
Why?
| | Light | 4 | 2009 | 395 | 0.180 |
Why?
| | Retinal Rod Photoreceptor Cells | 3 | 2018 | 18 | 0.180 |
Why?
| | Reoperation | 1 | 2024 | 592 | 0.180 |
Why?
| | Gene Frequency | 2 | 2025 | 494 | 0.180 |
Why?
| | Immunohistochemistry | 5 | 2020 | 1739 | 0.170 |
Why?
| | Neoplasms | 1 | 2016 | 2747 | 0.170 |
Why?
| | Receptor, Melatonin, MT1 | 2 | 2011 | 6 | 0.170 |
Why?
| | Diagnosis, Differential | 1 | 2025 | 1502 | 0.170 |
Why?
| | MutS Homolog 2 Protein | 1 | 2020 | 13 | 0.160 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2021 | 151 | 0.160 |
Why?
| | Thyroiditis, Autoimmune | 1 | 2020 | 15 | 0.160 |
Why?
| | Pheochromocytoma | 1 | 2021 | 58 | 0.160 |
Why?
| | Night Blindness | 2 | 2012 | 6 | 0.160 |
Why?
| | Paraganglioma | 1 | 2021 | 53 | 0.160 |
Why?
| | Calcitonin | 1 | 2020 | 29 | 0.160 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2021 | 184 | 0.160 |
Why?
| | Haemophilus influenzae type b | 1 | 2020 | 12 | 0.160 |
Why?
| | Trans-Activators | 2 | 2021 | 394 | 0.160 |
Why?
| | Neisseria meningitidis | 1 | 2020 | 25 | 0.160 |
Why?
| | Organizational Case Studies | 1 | 2020 | 78 | 0.160 |
Why?
| | Receptors, Virus | 1 | 2020 | 96 | 0.160 |
Why?
| | Tyrosine | 1 | 2000 | 228 | 0.160 |
Why?
| | Myopia | 2 | 2012 | 55 | 0.150 |
Why?
| | Neuroendocrine Tumors | 1 | 2021 | 110 | 0.150 |
Why?
| | Precision Medicine | 1 | 2024 | 434 | 0.150 |
Why?
| | Software | 1 | 2025 | 678 | 0.150 |
Why?
| | Disease Susceptibility | 2 | 2020 | 353 | 0.150 |
Why?
| | Animals | 25 | 2021 | 37749 | 0.150 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2021 | 1435 | 0.150 |
Why?
| | Retrospective Studies | 4 | 2025 | 16374 | 0.150 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2020 | 175 | 0.150 |
Why?
| | Crk-Associated Substrate Protein | 1 | 2018 | 4 | 0.150 |
Why?
| | DNA Mutational Analysis | 1 | 2020 | 398 | 0.150 |
Why?
| | Focal Adhesion Kinase 1 | 1 | 2018 | 30 | 0.150 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1977 | 0.150 |
Why?
| | Immune System | 1 | 2020 | 183 | 0.150 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2018 | 57 | 0.150 |
Why?
| | Leukocytes | 1 | 2020 | 309 | 0.140 |
Why?
| | Prevalence | 1 | 2025 | 2799 | 0.140 |
Why?
| | src-Family Kinases | 1 | 2018 | 94 | 0.140 |
Why?
| | Pharmacogenomic Variants | 1 | 2018 | 33 | 0.140 |
Why?
| | Streptococcus pneumoniae | 1 | 2020 | 169 | 0.140 |
Why?
| | DNA Mismatch Repair | 1 | 2018 | 47 | 0.140 |
Why?
| | Adrenal Cortex | 1 | 2018 | 33 | 0.140 |
Why?
| | Rod Opsins | 2 | 2009 | 7 | 0.140 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 263 | 0.130 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 35 | 0.130 |
Why?
| | Oncogenes | 1 | 2018 | 118 | 0.130 |
Why?
| | Postoperative Complications | 2 | 2023 | 2821 | 0.130 |
Why?
| | Dark Adaptation | 3 | 2018 | 13 | 0.130 |
Why?
| | Neoplasm Grading | 1 | 2018 | 316 | 0.130 |
Why?
| | Genetic Predisposition to Disease | 1 | 2025 | 2375 | 0.130 |
Why?
| | United States | 3 | 2025 | 15310 | 0.130 |
Why?
| | Middle Aged | 6 | 2025 | 34647 | 0.130 |
Why?
| | Telomerase | 1 | 2019 | 247 | 0.130 |
Why?
| | Amino Acids | 1 | 2000 | 497 | 0.120 |
Why?
| | Electroretinography | 5 | 2018 | 51 | 0.120 |
Why?
| | Photic Stimulation | 2 | 2008 | 256 | 0.120 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2018 | 199 | 0.120 |
Why?
| | Combined Modality Therapy | 2 | 2018 | 1249 | 0.120 |
Why?
| | Female | 11 | 2025 | 75943 | 0.120 |
Why?
| | Male | 14 | 2025 | 70179 | 0.120 |
Why?
| | Gene Expression Profiling | 2 | 2020 | 1771 | 0.120 |
Why?
| | Caspase 7 | 1 | 2015 | 22 | 0.120 |
Why?
| | Tyrosine 3-Monooxygenase | 3 | 2018 | 73 | 0.120 |
Why?
| | Tumor Suppressor Proteins | 1 | 2018 | 326 | 0.120 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2019 | 431 | 0.120 |
Why?
| | Disease Management | 1 | 2020 | 633 | 0.120 |
Why?
| | Bortezomib | 1 | 2015 | 53 | 0.120 |
Why?
| | Information Storage and Retrieval | 1 | 2016 | 120 | 0.120 |
Why?
| | Inhibitory Concentration 50 | 1 | 2015 | 91 | 0.120 |
Why?
| | Hypocalcemia | 1 | 2015 | 35 | 0.120 |
Why?
| | User-Computer Interface | 1 | 2016 | 164 | 0.120 |
Why?
| | Diabetic Retinopathy | 1 | 2018 | 201 | 0.120 |
Why?
| | Radiation, Ionizing | 1 | 2015 | 80 | 0.120 |
Why?
| | Mice | 13 | 2021 | 18109 | 0.110 |
Why?
| | Cell Proliferation | 3 | 2021 | 2506 | 0.110 |
Why?
| | Taxoids | 1 | 2015 | 102 | 0.110 |
Why?
| | Disease Progression | 2 | 2020 | 2800 | 0.110 |
Why?
| | Pharmacogenetics | 1 | 2016 | 168 | 0.110 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 1057 | 0.110 |
Why?
| | Genetic Testing | 1 | 2018 | 463 | 0.110 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2019 | 529 | 0.110 |
Why?
| | Mice, Knockout | 6 | 2018 | 3071 | 0.110 |
Why?
| | Caspase 3 | 1 | 2015 | 250 | 0.110 |
Why?
| | Prognosis | 2 | 2024 | 4080 | 0.110 |
Why?
| | Cross-Sectional Studies | 1 | 2025 | 5697 | 0.110 |
Why?
| | Cell Death | 1 | 2015 | 387 | 0.100 |
Why?
| | Promoter Regions, Genetic | 1 | 2018 | 1243 | 0.100 |
Why?
| | Computational Biology | 1 | 2018 | 664 | 0.100 |
Why?
| | Interleukin-8 | 1 | 2014 | 273 | 0.100 |
Why?
| | Rats | 6 | 2010 | 5637 | 0.100 |
Why?
| | Phosphorylation | 2 | 2008 | 1774 | 0.100 |
Why?
| | Neoplasm Transplantation | 3 | 2019 | 250 | 0.100 |
Why?
| | Aged | 4 | 2025 | 24746 | 0.100 |
Why?
| | Neovascularization, Pathologic | 1 | 2014 | 296 | 0.090 |
Why?
| | Molecular Targeted Therapy | 1 | 2015 | 420 | 0.090 |
Why?
| | Models, Biological | 1 | 2020 | 1828 | 0.090 |
Why?
| | Macrophages | 1 | 2020 | 1562 | 0.090 |
Why?
| | Retinal Bipolar Cells | 1 | 2012 | 7 | 0.090 |
Why?
| | Mice, Nude | 3 | 2021 | 691 | 0.090 |
Why?
| | Gene Expression Regulation | 3 | 2012 | 2608 | 0.090 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 1793 | 0.090 |
Why?
| | Calcium | 2 | 2015 | 1192 | 0.090 |
Why?
| | Dopamine Agonists | 2 | 2008 | 43 | 0.090 |
Why?
| | Protein Kinase Inhibitors | 3 | 2023 | 919 | 0.080 |
Why?
| | Dopamine beta-Hydroxylase | 1 | 2010 | 14 | 0.080 |
Why?
| | Rats, Wistar | 3 | 2001 | 455 | 0.080 |
Why?
| | Disulfiram | 1 | 2010 | 15 | 0.080 |
Why?
| | Homovanillic Acid | 2 | 2000 | 10 | 0.080 |
Why?
| | Alcohol Deterrents | 1 | 2010 | 19 | 0.080 |
Why?
| | Algorithms | 1 | 2018 | 1768 | 0.080 |
Why?
| | Conditioning, Operant | 1 | 2010 | 103 | 0.080 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2012 | 226 | 0.080 |
Why?
| | Mice, Inbred C57BL | 5 | 2018 | 5909 | 0.080 |
Why?
| | Obesity | 1 | 2023 | 3008 | 0.080 |
Why?
| | Extinction, Psychological | 1 | 2010 | 88 | 0.080 |
Why?
| | Chickens | 2 | 2006 | 189 | 0.080 |
Why?
| | Vision, Ocular | 1 | 2009 | 46 | 0.080 |
Why?
| | Light Signal Transduction | 1 | 2009 | 7 | 0.080 |
Why?
| | Amacrine Cells | 1 | 2009 | 13 | 0.070 |
Why?
| | Cyclic AMP | 2 | 2006 | 219 | 0.070 |
Why?
| | Cocaine | 1 | 2010 | 173 | 0.070 |
Why?
| | Dopamine Antagonists | 1 | 2008 | 25 | 0.070 |
Why?
| | Receptors, Dopamine D4 | 1 | 2008 | 25 | 0.070 |
Why?
| | Cells, Cultured | 4 | 2014 | 4212 | 0.070 |
Why?
| | Adult | 3 | 2025 | 39391 | 0.070 |
Why?
| | Chromatography, High Pressure Liquid | 3 | 2011 | 595 | 0.070 |
Why?
| | Visual Pathways | 1 | 2008 | 59 | 0.070 |
Why?
| | Disease Models, Animal | 3 | 2019 | 4421 | 0.070 |
Why?
| | Apoptosis | 3 | 2021 | 2576 | 0.070 |
Why?
| | Retinal Diseases | 1 | 2008 | 96 | 0.060 |
Why?
| | Nerve Growth Factors | 1 | 2007 | 79 | 0.060 |
Why?
| | Adenylyl Cyclases | 1 | 2006 | 63 | 0.060 |
Why?
| | Mammals | 1 | 2008 | 287 | 0.060 |
Why?
| | Calmodulin | 1 | 2006 | 71 | 0.060 |
Why?
| | Treatment Outcome | 4 | 2024 | 11181 | 0.060 |
Why?
| | Darkness | 2 | 2009 | 27 | 0.060 |
Why?
| | RNA, Messenger | 6 | 2012 | 2828 | 0.060 |
Why?
| | Arylamine N-Acetyltransferase | 1 | 2005 | 7 | 0.060 |
Why?
| | Imidazoles | 2 | 2021 | 255 | 0.060 |
Why?
| | Neck Dissection | 1 | 2024 | 18 | 0.060 |
Why?
| | Enzyme Activation | 1 | 2006 | 811 | 0.060 |
Why?
| | Recurrent Laryngeal Nerve Injuries | 1 | 2024 | 16 | 0.060 |
Why?
| | Retinal Ganglion Cells | 1 | 2005 | 117 | 0.050 |
Why?
| | Early Growth Response Protein 1 | 1 | 2023 | 29 | 0.050 |
Why?
| | Genetics, Population | 1 | 2025 | 209 | 0.050 |
Why?
| | Lymph Node Excision | 1 | 2024 | 169 | 0.050 |
Why?
| | Biological Specimen Banks | 1 | 2024 | 99 | 0.050 |
Why?
| | Fibronectins | 1 | 2023 | 136 | 0.050 |
Why?
| | Phenotype | 2 | 2023 | 3177 | 0.050 |
Why?
| | 1,2-Dimethylhydrazine | 1 | 2001 | 1 | 0.050 |
Why?
| | Median Eminence | 1 | 2001 | 5 | 0.040 |
Why?
| | Preoptic Area | 1 | 2001 | 8 | 0.040 |
Why?
| | Preoperative Care | 1 | 2024 | 372 | 0.040 |
Why?
| | Biogenic Monoamines | 1 | 2001 | 16 | 0.040 |
Why?
| | Suprachiasmatic Nucleus | 1 | 2001 | 19 | 0.040 |
Why?
| | Oximes | 1 | 2021 | 25 | 0.040 |
Why?
| | Risk Assessment | 2 | 2024 | 3508 | 0.040 |
Why?
| | Retinal Degeneration | 2 | 2012 | 39 | 0.040 |
Why?
| | Carcinogens | 1 | 2001 | 128 | 0.040 |
Why?
| | Indazoles | 1 | 2021 | 74 | 0.040 |
Why?
| | Models, Statistical | 1 | 2025 | 671 | 0.040 |
Why?
| | Protein Binding | 1 | 2006 | 2242 | 0.040 |
Why?
| | Computer Simulation | 1 | 2025 | 1015 | 0.040 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2021 | 90 | 0.040 |
Why?
| | Drug Synergism | 1 | 2021 | 375 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2003 | 1087 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2021 | 962 | 0.040 |
Why?
| | Validation Studies as Topic | 1 | 2019 | 22 | 0.040 |
Why?
| | Wnt Signaling Pathway | 1 | 2021 | 202 | 0.040 |
Why?
| | Dasatinib | 1 | 2018 | 56 | 0.040 |
Why?
| | Luminescence | 1 | 2018 | 37 | 0.040 |
Why?
| | Piperazines | 1 | 2021 | 373 | 0.040 |
Why?
| | Pineal Gland | 2 | 2012 | 16 | 0.040 |
Why?
| | Genome-Wide Association Study | 1 | 2025 | 1406 | 0.030 |
Why?
| | Aldosterone | 1 | 2018 | 43 | 0.030 |
Why?
| | Neurons | 1 | 2007 | 1621 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2021 | 907 | 0.030 |
Why?
| | Oscillometry | 1 | 2018 | 36 | 0.030 |
Why?
| | Cell Survival | 2 | 2012 | 1134 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2025 | 2135 | 0.030 |
Why?
| | Germ-Line Mutation | 1 | 2018 | 168 | 0.030 |
Why?
| | Drug Interactions | 2 | 2010 | 406 | 0.030 |
Why?
| | Chick Embryo | 2 | 2006 | 133 | 0.030 |
Why?
| | Blotting, Western | 2 | 2011 | 1234 | 0.030 |
Why?
| | Norepinephrine | 2 | 2010 | 193 | 0.030 |
Why?
| | In Situ Hybridization | 2 | 2007 | 320 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 547 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2024 | 5212 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 1014 | 0.030 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2014 | 50 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2007 | 987 | 0.030 |
Why?
| | I-kappa B Proteins | 1 | 2014 | 76 | 0.030 |
Why?
| | Cell Line | 1 | 2019 | 2887 | 0.030 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2014 | 108 | 0.030 |
Why?
| | Colorado | 1 | 2024 | 4629 | 0.030 |
Why?
| | Body Weight | 1 | 2018 | 997 | 0.030 |
Why?
| | Mucoproteins | 1 | 2012 | 8 | 0.020 |
Why?
| | Opsins | 1 | 2012 | 10 | 0.020 |
Why?
| | Bromodeoxyuridine | 1 | 2012 | 80 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2012 | 116 | 0.020 |
Why?
| | Nerve Tissue Proteins | 2 | 2006 | 605 | 0.020 |
Why?
| | Oncogene Proteins | 1 | 2012 | 63 | 0.020 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2012 | 157 | 0.020 |
Why?
| | Eye Diseases, Hereditary | 1 | 2012 | 13 | 0.020 |
Why?
| | Genetic Diseases, X-Linked | 1 | 2012 | 24 | 0.020 |
Why?
| | Receptors, Metabotropic Glutamate | 1 | 2012 | 38 | 0.020 |
Why?
| | Mice, Inbred C3H | 1 | 2012 | 270 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2014 | 676 | 0.020 |
Why?
| | Transcription Factors | 2 | 2012 | 1712 | 0.020 |
Why?
| | Heterozygote | 1 | 2012 | 308 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2012 | 333 | 0.020 |
Why?
| | Chromosome Mapping | 1 | 2012 | 504 | 0.020 |
Why?
| | Thiones | 1 | 2010 | 14 | 0.020 |
Why?
| | Pedigree | 1 | 2012 | 511 | 0.020 |
Why?
| | Self Administration | 1 | 2010 | 126 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2012 | 1321 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2012 | 439 | 0.020 |
Why?
| | Adaptation, Biological | 1 | 2009 | 54 | 0.020 |
Why?
| | Food | 1 | 2010 | 163 | 0.020 |
Why?
| | Transducin | 1 | 2009 | 42 | 0.020 |
Why?
| | GTP-Binding Protein alpha Subunits | 1 | 2009 | 16 | 0.020 |
Why?
| | Retinal Cone Photoreceptor Cells | 1 | 2009 | 21 | 0.020 |
Why?
| | CLOCK Proteins | 1 | 2008 | 9 | 0.020 |
Why?
| | Periodicity | 1 | 2008 | 57 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2009 | 191 | 0.020 |
Why?
| | Sensory Deprivation | 1 | 2008 | 15 | 0.020 |
Why?
| | Feedback, Physiological | 1 | 2008 | 81 | 0.020 |
Why?
| | Young Adult | 1 | 2024 | 13749 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2015 | 3597 | 0.020 |
Why?
| | Blood Glucose | 1 | 2018 | 2278 | 0.020 |
Why?
| | Zebrafish | 1 | 2012 | 504 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2008 | 309 | 0.020 |
Why?
| | Proteoglycans | 1 | 2008 | 109 | 0.020 |
Why?
| | Calcium Channel Agonists | 1 | 2006 | 12 | 0.020 |
Why?
| | Flavoproteins | 1 | 2006 | 8 | 0.020 |
Why?
| | ARNTL Transcription Factors | 1 | 2006 | 17 | 0.020 |
Why?
| | 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 1 | 2005 | 1 | 0.020 |
Why?
| | Quinpirole | 1 | 2005 | 10 | 0.020 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2007 | 141 | 0.020 |
Why?
| | Photoperiod | 1 | 2006 | 53 | 0.020 |
Why?
| | Kainic Acid | 1 | 2005 | 34 | 0.020 |
Why?
| | Cryptochromes | 1 | 2006 | 25 | 0.020 |
Why?
| | Excitatory Amino Acid Agonists | 1 | 2005 | 41 | 0.010 |
Why?
| | Microscopy, Confocal | 1 | 2007 | 324 | 0.010 |
Why?
| | Cell Nucleus | 1 | 2009 | 609 | 0.010 |
Why?
| | Calcium Channel Blockers | 1 | 2006 | 172 | 0.010 |
Why?
| | Rats, Inbred F344 | 1 | 2005 | 269 | 0.010 |
Why?
| | Receptors, Dopamine D2 | 1 | 2005 | 96 | 0.010 |
Why?
| | Adolescent | 1 | 2024 | 22130 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2010 | 2525 | 0.010 |
Why?
| | Calcium Signaling | 1 | 2006 | 250 | 0.010 |
Why?
| | Animals, Newborn | 1 | 2007 | 870 | 0.010 |
Why?
| | Physical Conditioning, Animal | 1 | 2006 | 254 | 0.010 |
Why?
| | Prospective Studies | 1 | 2015 | 7777 | 0.010 |
Why?
| | Hydroxyindoleacetic Acid | 1 | 2001 | 26 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 2064 | 0.010 |
Why?
| | Injections, Subcutaneous | 1 | 2001 | 166 | 0.010 |
Why?
| | Prodrugs | 1 | 2001 | 46 | 0.010 |
Why?
| | Gene Expression | 1 | 2006 | 1492 | 0.010 |
Why?
| | Membrane Proteins | 1 | 2006 | 1158 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2001 | 771 | 0.010 |
Why?
| | Aging | 1 | 2009 | 1924 | 0.010 |
Why?
| | Reactive Oxygen Species | 1 | 2001 | 634 | 0.010 |
Why?
| | Intestines | 1 | 2001 | 357 | 0.010 |
Why?
| | Brain | 1 | 2010 | 2868 | 0.010 |
Why?
| | Time Factors | 1 | 2005 | 6966 | 0.010 |
Why?
|
|
Pozdeyev's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|